Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

May 6, 2016

Washington, DC
Marriott Marquis

The Illusive Irritable Bowel
Syndrome with Diarrhea

Targeting Etiology with Emerging Therapies

May 6, 2016
6:00 pm – 8:00 pm
Marriott Marquis
Meeting Level M2, Marquis Salon 1-4
Washington, DC

This event is not a part of the official Internal Medicine Meeting 2016 Education Program.

Join us in Washington, DC on May 6 at 6:00 pm for an interactive symposium featuring Drs. Talley, Lacy, and Moshiree as they provide practical guidance on the optimal clinical use of emerging agents and evolving treatment paradigms in IBS-D. This event will include presentations, case studies, and a panel discussion that highlight new therapies, how to use them in combination with other supportive therapies, diagnosing underlying etiology, and a review of therapies under investigation.



Nicholas Talley, MD, PhD
Mayo Clinic
Rochester, Minnesota

Brian E. Lacy, MD, PhD
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire

Baharak Moshiree, MD, MS
University of Miami Health System
Miami, Florida


Scientific Agenda

Friday, May 6, 2016

6:00 PM

Registration and dinner

6:30 PM

Welcome & introduction
Nicholas Talley, MD, PhD

6:35 PM

Demographic and baseline knowledge/competence polling
Nicholas Talley, MD, PhD

6:40 PM

Current updates in IBS-D
Nicholas Talley, MD, PhD

7:00 PM

Case #1: Diagnosing and managing bacterial disturbances in IBS-D
Brian E. Lacy, MD, PhD

7:20 PM

Case #2: Diagnosing and managing motility disorders in IBS-D
Baharak Moshiree, MD, MS

7:40 PM

Post-session knowledge/competence polling
Nicholas Talley, MD, PhD

7:55 PM

Recap of key points and closing remarks
Nicholas Talley, MD, PhD

8:00 PM



Continuing Education

Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

Imedex, LLC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC)

Successful completion of this CME activity enables a participant to earn up to 1.5 MOC points towards the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Points.

Who Should Attend

This educational activity is designed to meet the educational needs of internal medical physicians, primary care physicians, gastroenterologists, and other healthcare professionals (physician assistants, physicians-in-training, nurses, pharmacists, etc.) who are involved and/or interested in the treatment of patients with IBS-D.


After successful completion of this activity, participants should be able to:

  • Assess the pathophysiology of IBS-D, the various etiologies that may contribute to the disease, and how current therapies target these underlying causes
  • Assess current diagnostic criteria and testing options for IBS-D
  • Evaluate the latest therapies for IBS-D, their mechanism of action, and how they should be used in clinical practice
  • Evaluate the use of combination therapy in IBS-D



Registration is Complimentary!

To Register: You may register here by May 1, 2016 or by calling Imedex at +1 (800) 233 0957 (international callers please call +1 (678) 242 0906). For assistance, please contact Registration confirmations will be issued before the meeting.

Available seating will be based on room capacity. Seating is limited and pre-registration does not guarantee admission, as the room may be overbooked. Early arrival is recommended and seating will be first come first serve until capacity is met.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.



The following company has provided an educational grant in support of this symposium:
Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America, LLC



11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334

For registration inquiries:
Tel.: +1 (800) 233 0957
Direct: +1 (678) 242 0906
Fax: +1 (678) 242-0870